Article

Identifying the Common Cell-Free DNA Biomarkers across Seven Major Cancer Types

2023-06-05

Abstract excerpt

Blood-based circulating cell free DNA(cfDNA) detection offers a non-invasive and easily accessible way for early cancer detection. Despite the extensive utility of cfDNA, there are still many challenges to develop the clinical biomarkers. For example, cfDNA with genetic alterations often compose a small portion of the DNA circulating in plasma, which can be confounded by cfDNA contributed by normal cells. Therefor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b5cb3c4-31f5-5126-914e-bc3935ebda38
DOI: 10.20944/preprints202306.0288.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identifying the Common Cell-Free DNA Biomarkers across Seven Major Cancer TypesDOI 10.20944/preprints202306.0288.v1Read

Baseline mutation profiling of 1134 samples of circulating cell-free DNA and blood cells from healthy individualsSemantic proximity Read

Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer ManagementSemantic proximity Read

Bioinformatics Analysis for Circulating Cell-Free DNA in CancerSemantic proximity Read

Detection of Circulating Tumor DNA in Plasma Using Targeted Sequencing.Semantic proximity Read

Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Semantic proximity Read

Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learningSemantic proximity Read

Cell‐free DNA‐associated multi‐feature applications in cancer diagnosis and treatmentSemantic proximity Read

Towards systematic nomenclature for cell-free DNASemantic proximity Read

Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) studySemantic proximity Read

Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.Semantic proximity Read

Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes predictionSemantic proximity Read

Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 casesSemantic proximity Read